Objective: Prior meta-analysis indicates that collaborative chronic care models (CCMs) improve mental and physical health outcomes for individuals with mental disorders. This study aimed to investigate the stability of evidence over time and identify patient and intervention factors associated with CCM effects to facilitate implementation and sustainability of CCMs in clinical practice.
T here is growing evidence that collaborative chronic care models (CCMs) are effective across a broad range of mental health conditions treated across primary care and specialty mental health settings. 1 These models, originally described by Wagner and colleagues, [2] [3] [4] [5] [6] [7] involved several of a set of 4 elements: self-management support to help patients take a more active role in their care; clinical information systems, such as provider feedback and electronic registries; delivery system redesign to support prevention-oriented clinical care; and decision support, such as the use of treatment guidelines or expert consultants. Two additional core components were later added: health care organization support by local leadership and linkages to community resources, 5, 6 bringing the total number of CCM elements to 6. Given the strong evidence base for CCMs in mental disorders, 1, [7] [8] [9] the key issue becomes how best to implement and sustain these models in practice. [10] [11] [12] [13] Several specific questions arise. First, are any of the 6 elements essential for CCM effects, and are any superfluous? Second, what are the populations and settings most likely to benefit from CCMs? Finally, looking within studies, are there intermediate clinical processes that link the CCM elements to their clinical effects, such as medication prescription indicators?
Existing reviews of CCMs for medical illnesses have been inconclusive regarding which elements are required for CCM effects 4 but have provided some clues regarding key populations or clinical processes. Patients suffering from more severe illness may be more likely to benefit from CCMs, 4 and adherence to treatment guidelines by clinicians may be an important intermediary of CCM outcomes. [4] [5] [6] There have been no comprehensive reviews of how specific CCM elements, setting/population factors, and intermediate clinical processes impact outcomes for mental health conditions. The most germane data come from a meta-analysis focused on primary care depression trials, which indicated that several provider-level factors and process variables may predict CCM effects. 9 One descriptive review also investigated CCMs for depression in primary care, 14 and found that interventions featuring the first 4 CCM elements mentioned above were generally effective. That study did not explore the role of particular elements in predicting outcomes.
We therefore utilized extensive data obtained in our previous systematic review and meta-analysis 1 to attempt to identify the factors associated with CCM success for mental health conditions. First, we used cumulative meta-analysis to determine to what extent clinical trial effect sizes for CCMs have achieved statistical significance over time for key outcome domains. Second, we used descriptive and bivariate analyses to determine whether individual CCM elements or other trial characteristics (eg, populations or settings) were related to outcomes; to our knowledge this is the first review to explore the possible relationship between specific CCM elements and clinical outcomes across mental health conditions. We also descriptively reviewed and summarized the role of intermediate clinical processes of care that could be responsible for CCMs' clinical effects. Once again, a unique contribution of this study is its consideration of these factors across mental health CCMs. Third, we used metaregression to quantitatively determine whether any of these factors are associated with positive clinical outcomes. Fourth, we supplemented these analyses with a descriptive review of determinants of CCM effects identified within individual CCM trials themselves.
METHODS

Search Strategy and Study Identification
This study is based on a subset of trials from our initial meta-analysis. 1 CCMs were defined a priori as interventions with at least 3 of the 6 elements mentioned above; k for interrater agreement in identifying CCMs was 1.00, and intraclass correlation for the number of CCM elements present was 0.93. 1 In our initial study, trials with 2 or fewer CCM elements were excluded (the most common reason for exclusion), as were studies that did not assess our main outcomes (explained below) and those that only compared 2 CCM conditions without including a non-CCM control group. This study was exempt from human subjects research oversight as it only reviewed published studies.
Data Extraction
We focused on 3 clinical outcome domains that were reported in at least 15 trials from our original review, in order to identify domains likely to have sufficient numbers of studies for quantitative analyses. Three domains met this criterion: depression, mental quality of life (QOL), and physical QOL. Data were extracted when reported regardless of the primary diagnosis being targeted, as in the original meta-analysis, and further detail on these domains can be found in the results below.
We identified which of the 6 CCM elements an intervention included, as well as population, setting, and other trial implementation factors identified by the investigators a priori ( Table 1 ). Shared decision-making, defined as the process by which patients and care providers mutually agree to a treatment plan, [15] [16] [17] [18] was included for exploratory purposes.
Analyses
First, we conducted cumulative meta-analysis 19, 20 to estimate the overall cumulative effect size as each study is added to the analysis over time. A cumulative effect size provides an estimate of how rapidly, and stably, evidence in an outcome domain converges around a particular effect size. We also conducted metaregression 21, 22 to determine whether individual CCM elements, population, setting, or other trial implementation factors, identified a priori, predicted outcome effect sizes across studies. For all outcome analyses, effect sizes were calculated using Cohen d 22,23 as in our prior meta-analyses. 1 Only a subset of studies provided sufficient information for meta-analysis (ie, reported mean, SD, and sample size for both the CCM and control condition). We therefore used w 2 tests (for categorical variables) and point-biserial correlations (for continuous variables) to determine whether any CCM elements, population, trial, or other implementation factors were associated with trials that resulted in statistically significant results (P < 0.05), among the larger body of studies that reported P-values. To further investigate possible predictors of CCM effects, we supplemented quantitative between-study analyses with a descriptive summary review of data relevant to potential CCM mechanisms reported within individual trials.
RESULTS
Fifty-three trials published between 1994 and 2010 reported depression, mental QOL, or physical QOL outcomes. Of these, 46 reported results for depressive symptoms, assessed through a variety of measures including the Center for Epidemiological Studies Depression Scale, 76 the Beck Depression Inventory, 77 the Hamilton Depression Scale, 78 and the Hopkins Symptom Checklist-20-item version depression subscale. 79 A total of 20 trials reported results for mental QOL and 18 for physical QOL; nearly all studies assessing QOL on the basis of either the Short Form Health Survey 36-item 80 or 12-item version. 81 Further detail on individual study characteristics can be found in the e-tables, Supplemental Digital Content 1, http://links. lww.com/MLR/A534.
The most commonly targeted diagnosis among reviewed trials was depression (n = 39), followed by bipolar disorder (n = 4), anxiety disorders (n = 3), and mixed or multiple disorders (in some cases including physical comorbidities; n = 10). Several trials contributed outcomes in multiple domains, which were analyzed independently.
Thirteen of these trials included meta-analyzable outcomes for depressive symptoms, and 6 each for mental and physical QOL. Compared with studies included in the metaanalysis, those excluded were less likely to include the CCM element of clinical information systems (P < 0.001) and more frequently included health care organization support (P = 0.04).
Cumulative Meta-analysis
Cumulative meta-analysis of depression outcomes indicated an early effect of CCM that remained significant throughout subsequent studies ( Fig. 1 ). Cumulative effect sizes favoring CCM for mental and physical QOL achieved statistical significance more recently, in 2010 and 2008, respectively.
Cross-study Descriptive Analyses CCM Elements
Trial interventions contained 3.75 ± 0.65 elements (range, 3-6; Table 1 ). The 4 original CCM elements 2 (selfmanagement support, clinical information systems, delivery system redesign, and decision support) were present in at least 75% of trials. The 2 elements added later, 5, 6 health care organization support and linkages to community resources, were each present in only 8% of trials. The modal CCM trial (51%) featured the first 4 elements but not the last 2. Shared decision-making was explicitly mentioned in 30% of the trials. Table 2 . w 2 and point-biserial correlation results were nonsignificant for all analyses investigating the effect of these characteristics on outcomes for depression, mental quality of life, or physical quality of life (see text for details). The relative ubiquity of the first 4 CCM elements, combined with the relative rarity of the latter 2, makes quantitative analysis of particular elements on clinical outcomes difficult. Consistent with this, w 2 and point-biserial correlations indicated that no individual CCM element or shared decision-making was significantly associated with statistically significant outcomes among the reviewed trials. That is, studies that contained any particular CCM element did not demonstrate statistically greater improvements over control than did studies not containing that element.
Population, Setting, and Trial Implementation Factors
As with the CCM elements, w 2 and point-biserial correlations revealed no statistically significant effects on outcomes for individual population/setting factors including system setting, clinic setting, disorder/diagnosis, age, sex, or minority status. Thus, although CCMs led to statistically significant improvement compared with control conditions overall, no specific populations, settings, or trial characteristics were associated with larger differences from control. Likewise, trial implementation factors (type of control condition, US vs. non-US location, and trial length) were not associated with greater CCM success over control.
Metaregression Results
Initially, our metaregression was conducted in a multivariate manner, with each of over a dozen predictor variables entered simultaneously. This resulted in no statistically significant findings, and so we instead ran the metaregression as a series of bivariate analyses. Consistent with the multivariate metaregression, and with the cross-study descriptive analyses presented above, the bivariate metaregression analyses ( Table 2 ) did not reveal any CCM element or explicit mention of shared decision-making to be uniquely associated with better clinical outcomes. None of the population/setting or trial implementation factors achieved statistical significance by metaregression.
Descriptive Review of Findings Within Studies
To further investigate possible predictors of CCM effects, we supplemented quantitative between-study analyses with a review of data reported within individual trials and follow-up studies.
CCM Elements
Some studies in our sample included comparisons between multiple CCM interventions. One study 25 used a cluster-randomized design, and concluded that both patient self-management support and the more system-based CCM elements (clinical information systems, delivery system redesign, and clinical decision support) were both important in leading to improved outcomes. Another study 42 found that a relatively more intensive CCM intervention (featuring both patient self-management support and delivery system redesign) outperformed a less intensive intervention.
Population, Setting, and Trial Implementation Factors
Five studies 34, 50, 65, 68, 82 found CCM to be more likely to outperform the control condition for patients with moresevere symptoms when compared with those with less-severe symptoms. Two studies 45, 83 found CCM to be equally effective for more-severe and less-severe patient groups, and 2 others 33, 84 found that CCM did not outperform control regardless of initial depression severity. Regarding comorbidities, 1 study 85 found that patients with bipolar disorder and comorbid psychosis derived more benefit from the CCM relative to the control condition than did those without psychosis, whereas those with comorbid cardiovascular conditions derived less benefit than those without cardiovascular conditions, and those with substance or anxiety disorders showed no difference. Another study reported a trend for CCM to be more effective at reducing mortality for patients with depression and comorbid diabetes than depression alone. 86 Regarding race/ethnicity, 1 study found no difference in CCM compared with control based on minority status 55 ; another found that the CCM had greater effects among racial or ethnic minorities compared with whites. 87 Several studies featuring exclusively minority samples found that CCM outperformed the control condition, 46, 47, 60, 61 whereas others found no difference. 37, 62 Only 1 study explicitly investigated sex, finding CCM to be superior to control for men but not women. 26
Intermediate Clinical Processes
Fourteen trials found CCM to be associated with higher rates of prescriptions or dosages of antidepressants, 29, 35, 36, 45, 47, 50, 55, 61, 66, 67, 69, 70, 72, 73 although others found no such association. 30, 31, 53, 56, 63, 82 Other studies indicated that CCMs are associated with superior guideline adherence by clinicians. 54, 58, 59, 68 Only 1 study investigated formal mediation, 88, 89 finding that the CCM intervention was associated with improved clinician guideline adherence, which was in turn associated with improved outcomes in the CCM group. 54 Cumulative meta-analysis indicates that CCM effect sizes for depression and mental and physical QOL have achieved statistical significance, although QOL outcomes attained this status more recently than depression outcomes. The majority of trials have utilized the 4 original CCM elements (patient self-management support, clinical information systems, delivery system redesign, and provider decision support), whereas the 2 latter elements were utilized in only 8% of trials. Thus the modal trials featured all 4 elements but not the 2 elements added to the model later. The first 4 elements were frequently included in clinical trials by embedding care managers (itself a form of delivery system redesign) who provide self-management support to patients, clinical information systems in the form of registry tracking, and decision support by communicating with mental health specialists. Health care organization support and leadership are crucial, however, in moving from the controlled trial environment to implementation 10, 12, 90, 91 and sustainability 13, 92 in clinical practice.
DISCUSSION
Major Findings in Context
Metaregression did not reveal association of specific CCM elements or shared decision-making with CCM effects, possibly because of skewed distribution of individual elements across CCMs. Thus, there is insufficient evidence at this time to conclude that any single element is essential, or superfluous, to the model. These results mirror previous qualitative reviews of CCMs applied to physical health conditions in primary care. 4 Recent metaregressions of elements of CCMs for heart failure have also been heterogenous, with one identifying involvement of multiple disciplines as predictive of better outcomes, 93 but another finding no relationship between the number of CCM elements and outcomes. 94
Population, Setting, and Trial Implementation Factors
Although metaregression analyses did not identify specific population, setting, or trial implementation factors associated with better or worse CCM performance, review of individual studies provided some insights. Most notably, a majority of relevant studies 34, 50, 65, 68, 82 indicated that those with moderate to severe symptoms may benefit more than those with milder symptoms. Similarly, one study in bipolar disorder indicated that psychotic features (associated with more severe illness) predicted better outcomes, while substance and anxiety disorder comorbidity did not diminish effects. 85 This suggests the potential usefulness of stepped care, that is, gradations of care intensity for different severities of illness or comorbidities. 95 With the exception of illness severity, we could not identify other factors associated with greater CCM effect. That is, although CCM generally outperformed control across the reviewed trials, we could not identify other populations or settings in which the gap between CCM and control was significantly larger. One interpretation of these findings is that CCMs are robust across different settings, disorders, and populations. Alternatively, metaregression may have been underpowered to detect significant effects.
Intermediate Clinical Processes
No intermediate clinical processes were reported in a sufficient number of trials to conduct between-study quantitative analyses. Only 1 study 57 performed a mediator analysis linking greater guideline concordance to improved outcome; however, descriptive intrastudy results suggest that medication prescriptions or adherence, as well as guideline concordance by clinicians, were higher for CCM than control subjects across relevant studies. Although it makes intuitive sense that improved pharmacological care and guideline concordance could be pathways through which CCMs exert clinical effects, the general lack of explicit mediator analyses within trials 88 makes reaching concrete conclusions difficult.
Future Directions
First, given that cumulative meta-analysis revealed stable effects for CCMs across disorders in the domains of depression, mental QOL, and physical QOL, a critical next step is identifying factors supporting implementation 10, 96 and sustainability 13, 92 of the model. Second, given the strength of the evidence base for CCMs targeting depression, 1, [7] [8] [9] additional RCTs for patients with depression in primary care are unlikely to appreciably expand our understanding of the model. Intervention development work is still needed, however, to optimally apply CCMs to evolving needs of other populations and settings. 1, 97 For instance, the first CCM trial in bipolar disorder demonstrated improved outcome in mental health measures, but not physical QOL 48, 49 ; subsequent model development more explicitly addressed physical health outcomes and demonstrated improvements in this outcome as well. 71, 98 Third, the development of more efficient CCM models may be especially important for spreading CCM interventions to smaller, less resource-flush practices in which the majority of psychiatrists and mental health practitioners work. 99 Future studies might use dismantling designs to compare 2 active CCM conditions differing by 1 or 2 different CCM elements. For example, 2 studies included in this review 25, 42 indicated that patient self-management support may add value above and beyond other CCM elements. Such designs will likely require larger samples than was typically seen in the studies we reviewed, as differences between 2 active CCM interventions may be expected to be smaller than differences between a CCM and control condition. Such studies could incorporate more detailed measures of the CCM elements (such as recording the number of care management contacts or attendance of therapy groups) to allow consideration of the CCM elements in a continuous rather than dichotomous (present vs. absent) manner. Many studies in this review included such measures, but without enough consistency to allow comprehensive cross-study comparisons.
Some, however, have argued that CCMs are in fact synergistic programs and that attempting to disaggregate elements in the service of efficiency "foster[s] the misconception that a single best type of programme can and does exist" 100 (page 1272). They recommend instead focusing on implementation factors such as local context that will lead to the development of complex-but implementable and sustainable-CCMs.
Finally, our review revealed surprisingly few data on intermediate clinical processes that might explain CCMs' effects on clinical outcomes. To further explore this domain would not require substantial changes to data collection or study design; rather, studies should explicitly report links among CCM interventions, potential mediators, and outcomes.
Limitations
Our characterization of CCM elements and design factors was limited by information provided in peerreviewed articles; however, we were nonetheless able to demonstrate high reliability in extracting data. Second, our analytic plan assumed that study characteristics were conceptually distinct and described in sufficient detail for extraction from empirical articles. This may not be the case, 100 as, for example, effective use of clinical information systems may depend on system redesign. Third, metaregression has relatively low power, particularly when the distribution of independent variables is not even, which was the case for the 6 CCM elements (Table 1) . Therefore, we supplemented metaregression with qualitative analyses, w 2 tests, and point-biserial correlations. Fourth, these latter strategies used study significance (based on reported P-values) as an outcome. Although such a "vote-counting" approach has important limitations, 101 it was the only way to quantify data from studies that could not be included in the metaregression. Fifth, despite our broad inclusion criteria, the majority of included studies targeted depression in primary care (and nearly all targeted mood or anxiety disorders). Nonetheless, this review represents the first attempt to systematically include mental health conditions other than depression. Sixth, nearly all studies that reported QOL results relied on the Short Form Health Survey, 80, 81 which may be limited in mental health conditions by a statistically imposed negative correlation between its mental and physical component scores. 102 It was, however, the only measure used consistently among the reviewed studies. Finally, although we are aware that our population/setting/trial factors and intermediate clinical processes are similar to the constructs of moderators and mediators, respectively, we avoided using these terms because such analyses typically require within-study data, 88, 89 and our analyses relied on predominantly cross-study analyses.
CONCLUSIONS
Cumulative meta-analysis has revealed significant CCM effects across study populations for depression and, more recently, mental and physical QOL outcomes. No single CCM element, or subset of CCM elements, appears essential to the model, although the 4 original CCM elements appear sufficient for effects in RCTs. Priorities moving forward include the development of implementation strategies that will support adoption and sustainability of the model in clinical practice. Additional supporting work is also needed in intervention development trials for specific subpopulations and settings. To the degree that CCM elements are in fact separable, dismantling studies can inform efficient model development, particularly investigating patient-versus systemor provider-level elements. Paramount in all these endeavors is supporting the fit of such multicomponent interventions to local context in a sustainable manner.
